Invitae Corporation (NVTA) Morgan Stanley 20th Annual Global Healthcare Conference Call September 13, 2022 8:00 AM ET
Company Participants
Ken Knight - Chief Executive Officer
Conference Call Participants
Tejas Savant - Morgan Stanley
Tejas Savant
Hey, everyone. Good morning. My name is Tejas Savant. And I am the life science tools and diagnostics analyst here at Morgan Stanley. It’s my pleasure to host Ken Knight, CEO of Invitae here. And again, thanks for joining us. Before we get started, I just have to read the research disclosures. For important disclosures, please see the Morgan Stanley website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your sales rep. So with that, Ken thanks again for joining us.
Ken Knight
Thank you.
Question-and-Answer Session
Q - Tejas Savant
Maybe just to set the stage, I mean, obviously, it’s been – it’s been a very eventful year for Invitae. Can you talk about sort of your key priorities heading into year end and into ‘23 after the restructuring? And what are you most looking forward to over the next 12 months?
Ken Knight
That’s quite a bit. And thank you Tejas for having us here. First of all, it’s great to be back in New York. I lived across the Holland Tunnel in New Jersey for about a decade, always exciting to come back into the city. And it’s glad that we can actually do some things back in person again. So first of all, glad to be here. As I think about our – my immediate priorities and the priorities of our company, we laid those out in our realignment announcement back in July, first of all increasing our cash runway that was important for us. As we looked at the availability of capital, we kind of recognized that in ensuring that we had sufficiency in our liquidity through the end of 2024 that
- Read more current NVTAQ analysis and news
- View all earnings call transcripts